Which neurotransmitter hypothesis of Major Depressive Disorder proposes a deficiency in monoamine neurotransmitters, particularly serotonin, norepinephrine, and dopamine?

Explanation

## The Monoamine Hypothesis of Depression **Key Point:** The **monoamine hypothesis** (also called the catecholamine hypothesis or biogenic amine hypothesis) posits that depression results from a deficiency of monoamine neurotransmitters — specifically **serotonin (5-HT)**, **norepinephrine (NE)**, and **dopamine (DA)** — in key brain regions. ### Historical Context This hypothesis emerged in the 1960s after the observation that: - Reserpine (which depletes monoamines) causes depression - Early antidepressants (TCAs, MAOIs) increase monoamine availability - SSRIs and SNRIs (which selectively enhance serotonin/norepinephrine) are effective ### The Three Monoamine Systems | Neurotransmitter | Key Brain Regions | Clinical Role in Depression | |---|---|---| | **Serotonin (5-HT)** | Raphe nuclei → limbic system, prefrontal cortex | Mood regulation, anxiety, sleep, appetite | | **Norepinephrine (NE)** | Locus coeruleus → cortex, limbic system | Attention, motivation, arousal, stress response | | **Dopamine (DA)** | Ventral tegmental area → nucleus accumbens, prefrontal cortex | Reward, motivation, pleasure (anhedonia when depleted) | **High-Yield:** The monoamine hypothesis is the neurobiological foundation for all modern antidepressant drug classes. NEET PG frequently tests the link between monoamine deficiency and antidepressant mechanism of action. ### Antidepressant Classes and Monoamine Action ```mermaid flowchart TD A[Monoamine Deficiency in Depression]:::outcome --> B{Antidepressant Class}:::decision B -->|SSRIs| C[↑ Serotonin reuptake inhibition]:::action B -->|SNRIs| D[↑ Serotonin + Norepinephrine reuptake inhibition]:::action B -->|TCAs| E[↑ All three monoamines reuptake inhibition]:::action B -->|MAOIs| F[↑ Monoamine degradation inhibition]:::action B -->|Atypical| G[Mixed mechanisms: DA, NE, 5-HT modulation]:::action C --> H[Clinical improvement in mood, anxiety, sleep]:::outcome D --> H E --> H F --> H G --> H ``` **Clinical Pearl:** While the monoamine hypothesis is the most widely accepted neurobiological model and guides pharmacotherapy, it does not fully explain depression's pathogenesis. Modern understanding incorporates neuroplasticity, HPA axis dysfunction, neuroinflammation, and genetic factors — but monoamine deficiency remains the primary therapeutic target. **Warning:** The monoamine hypothesis is a simplified model. Depression is multifactorial; correcting monoamine levels alone does not always produce remission, explaining why some patients are treatment-resistant. [cite:Harrison 21e Ch 470, Kaplan & Sadock Comprehensive Textbook of Psychiatry 11e]